Not provided
| ID | Type | Description | Link |
|---|---|---|---|
| H6Q-MC-S042 | Other Identifier | Eli Lilly and Company |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
To determine whether further study of single-agent enzastaurin is warranted in patients with previously treated Waldenstrom's Macroglobulinemia or Multiple Myeloma based on response.
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| A: Enzastaurin | Experimental |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Enzastaurin | Drug | Enzastaurin: Cycle 1 Day 1 only: 3, 125-milligrams (mg) tablets three times on Day 1 (Day 1 total dose = 1125 mg) Day 2 onwards and subsequent Cycles: 2, 125-mg tablets orally twice a day (500 mg total per day). Cycle length (all cycles): 28 days. Patients may stay on drug past 8 cycles, (until the study is closed) or until disease progression. |
| Measure | Description | Time Frame |
|---|---|---|
| Percentage of Participants With Complete Response (CR), Partial Response (PR) and Minimal Response (MR) or Minor Response (MinR): (Response Rate) | European Group for Blood and Bone Marrow Transplant (EBMT) Response Criteria (RC) used for MM. CR: no serum/urine M protein for 6 weeks (wk), <5% plasma cells in bone marrow (PCBM), no lytic bone lesions (LBL) size/number increase, no soft tissue plasmacytomas (STPC); PR: met some CR criteria plus maintain for 6 wk ≥50% serum monoclonal paraprotein (SPEP) and PCBM decrease, either decrease of ≥90% or <200 mg light chain excretion (LCE), ≥50% STPC size decrease; MR: met some PR criteria plus maintain for 6 wk, a decrease of: 25-49% SPEP, 50-89% 24 hour urinary LCE, 25-49% PCBM, 25-49% STPC size. International Workshop on WM (IWWM) RC used for WM. CR: no serum M protein, malignant cells in BM, or lymphadenopathy/organomegaly; PR: ≥50% immunoglobulin M (IgM) and adenopathy/organomegaly (A/O) decrease; no new symptoms of WM. MinR: ≥25% to <50% IgM decrease, no A/O progression; no cytopenias or clinical symptoms of WM. | Baseline to measured progressive disease up to 40.51 months |
| Measure | Description | Time Frame |
|---|---|---|
| Duration of Response (DOR) | DOR is defined as elapsed time from the first evidence of CR, PR, MR or MinR until date of progression of disease (PD). EBMT RC used for MM. CR: no serum/urine M protein for 6 wk, <5% PCBM, no LBL size/number increase, no STPC; PR: met some CR criteria plus maintain for 6 wk ≥50% SPEP and PCBM decrease, either decrease of ≥90% or <200 mg LCE, ≥50% STPC size decrease; MR: met some PR criteria plus maintain for 6 wk decrease of: 25-49% SPEP, 50-89% 24 hour urinary LCE, 25-49% PCBM, 25-49% STPC size. PD: >25% increase in SPEP, 24 hour urinary LCE, PCBM, STPC size increase, new bone lesion or STPC. IWWM RC used for WM. CR: no serum M protein, malignant cells in BM, or lymphadenopathy/organomegaly; PR: ≥50% IgM and A/O decrease; no new WM symptoms. MinR: ≥25% to <50% IgM decrease, no A/O progression; no cytopenias or clinical of WM symptoms. PD: >25% IgM increase, progression of clinical findings or symptoms. For participants who had no PD, DOR was censored at their last contact. |
| Measure | Description | Time Frame |
|---|---|---|
| Number of Participants Who Died Due to Progressive Disease During the 30 Days Following Discontinuation From Study Treatment | Study treatment discontinuation up to 30 days post study treatment discontinuation |
Inclusion Criteria:
At least 18 years of age.
Patients must have Waldenstrom's Macroglobulinemia (WM) or Multiple Myeloma (MM) previously treated with at least 1 and no more than 5 prior therapies.
Treatment with prior autologous transplant is permitted. If a transplant is used as consolidation following chemotherapy, without intervening disease progression, it will be considered 1 line of treatment with the preceding chemotherapy.
Patients with MM must have a monoclonal protein in the serum of greater than or equal to 1 gram per deciliter (g/dL) or monoclonal light chain in the urine protein electrophoresis of greater than or equal to 200 milligrams (mg)/ 24 hours, or measurable plasmacytoma.
Patients with WM must have an immunoglobulin M (IgM) paraprotein with a minimum IgM level of > 2 times the upper limit of normal (ULN), have detectable lymphoplasmacytic (LPL) cells in the bone marrow, and be symptomatic for WM.
Eastern Cooperative Oncology Group (ECOG) Performance Status (PS) of 0, 1, or 2.
The following laboratory values obtained prior to registration:
Expected survival of greater than 12 weeks.
The ability to provide informed consent.
Male and female patients with reproductive potential must use an approved contraceptive method, if appropriate (for example, intrauterine device [IUD], birth control pills, or barrier device) during and for 3 months after discontinuation of study treatment. Women with childbearing potential must have a negative serum pregnancy test less than or equal to 3 days prior to study enrollment
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon- Fri 9 AM- 5 PM Eastern time (UTC/GMT- 5 hours, EST) | Eli Lilly and Company | Study Director |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. | Boston | Massachusetts | 02115 |
Not provided
Not provided
Not provided
| ID | Title | Description |
|---|---|---|
| FG000 | Multiple Myeloma (MM) | Participants diagnosed with MM received: Three 125-milligrams (mg) Enzastaurin tablets three times on Day 1 of Cycle 1 (Day 1 total dose = 1125 mg). Day 2 onwards and subsequent Cycles: Two 125-mg tablets orally twice a day (500 mg total per day). Cycle length (all cycles): 28 days. |
| FG001 | Waldenstrom's Macroglobulinemia (WM) | Participants diagnosed with WM received: Three 125-milligrams (mg) Enzastaurin tablets three times on Day 1 of Cycle 1 (Day 1 total dose = 1125 mg). Day 2 onwards and subsequent Cycles: Two 125-mg tablets orally twice a day (500 mg total per day). Cycle length (all cycles): 28 days. |
| Title | Milestones | Reasons Not Completed | ||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Overall Study |
|
|
Not provided
Not provided
| ID | Title | Description |
|---|---|---|
| BG000 | Multiple Myeloma (MM) | Participants diagnosed with MM received: Three 125-milligrams (mg) Enzastaurin tablets three times on Day 1 of Cycle 1 (Day 1 total dose = 1125 mg). Day 2 onwards and subsequent Cycles: Two 125-mg tablets orally twice a day (500 mg total per day). Cycle length (all cycles): 28 days. |
| BG001 |
| Units | Counts |
|---|---|
| Participants |
|
| Title | Description | Population Description | Parameter Type | Dispersion Type | Unit of Measure | Calculate Percentage | Denominator Units Selected | Denominators | Classes |
|---|---|---|---|---|---|---|---|---|---|
| Age, Continuous | Mean |
| Type | Title | Description | Population Description | Reporting Status | Anticipated Posting Date | Parameter Type | Dispersion Type | Unit of Measure | Calculate Percentage | Time Frame | Units Analyzed | Denominator Units Selected | Arm/Group Information | Denominators | Classes | Analyses |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Primary | Percentage of Participants With Complete Response (CR), Partial Response (PR) and Minimal Response (MR) or Minor Response (MinR): (Response Rate) | European Group for Blood and Bone Marrow Transplant (EBMT) Response Criteria (RC) used for MM. CR: no serum/urine M protein for 6 weeks (wk), <5% plasma cells in bone marrow (PCBM), no lytic bone lesions (LBL) size/number increase, no soft tissue plasmacytomas (STPC); PR: met some CR criteria plus maintain for 6 wk ≥50% serum monoclonal paraprotein (SPEP) and PCBM decrease, either decrease of ≥90% or <200 mg light chain excretion (LCE), ≥50% STPC size decrease; MR: met some PR criteria plus maintain for 6 wk, a decrease of: 25-49% SPEP, 50-89% 24 hour urinary LCE, 25-49% PCBM, 25-49% STPC size. International Workshop on WM (IWWM) RC used for WM. CR: no serum M protein, malignant cells in BM, or lymphadenopathy/organomegaly; PR: ≥50% immunoglobulin M (IgM) and adenopathy/organomegaly (A/O) decrease; no new symptoms of WM. MinR: ≥25% to <50% IgM decrease, no A/O progression; no cytopenias or clinical symptoms of WM. | All participants who received at least one dose of the study drug. | Posted | Number | percentage of participants | Baseline to measured progressive disease up to 40.51 months |
Not provided
Deaths due to progressive disease are not considered adverse events; however they are reported in the Participant Flow for those who died during the study and in the Other Pre-Specified Outcome Measure for those who died during the 30-day post study treatment follow-up period.
Not provided
| ID | Title | Description | Deaths (Affected) | Deaths (At Risk) | Serious Events (Affected) | Serious Events (At Risk) | Other Events (Affected) | Other Events (At Risk) |
|---|---|---|---|---|---|---|---|---|
| EG000 | Multiple Myeloma (MM) | Participants diagnosed with MM received: Three 125-milligrams (mg) Enzastaurin tablets three times on Day 1 of Cycle 1 (Day 1 total dose = 1125 mg). Day 2 onwards and subsequent Cycles: Two 125-mg tablets orally twice a day (500 mg total per day). Cycle length (all cycles): 28 days. |
| Term | Organ System | Source Vocabulary | Assessment Type | Notes | Statistical Information |
|---|---|---|---|---|---|
| Anaemia | Blood and lymphatic system disorders | 15.0 | Systematic Assessment |
| Term | Organ System | Source Vocabulary | Assessment Type | Notes | Statistical Information |
|---|---|---|---|---|---|
| Anaemia | Blood and lymphatic system disorders | 15.0 | Systematic Assessment |
Not provided
| Title | Organization | Phone | Extension | |
|---|---|---|---|---|
| Chief Medical Officer | Eli Lilly and Company | 800-545-5979 | ClinicalTrials.gov@lilly.com |
Not provided
| ID | Term |
|---|---|
| D008258 | Waldenstrom Macroglobulinemia |
| D009101 | Multiple Myeloma |
| ID | Term |
|---|---|
| D054219 | Neoplasms, Plasma Cell |
| D009370 | Neoplasms by Histologic Type |
| D009369 | Neoplasms |
| D020141 | Hemostatic Disorders |
Not provided
Not provided
| ID | Term |
|---|---|
| C504878 | enzastaurin |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
|
|
| Time of response to time of measured progressive disease up to 38.37 months |
| Time to Progressive Disease | Time to progression is defined as the elapsed time from the date of study enrollment to the date of objectively determined progressive disease (PD). European Group for Blood and Bone Marrow Transplant (EBMT) Response Criteria was used for MM. PD: >25% increase in serum monoclonal paraprotein (SPEP), 24 hour urinary light chain excretion (LCE), plasma cells in bone marrow (PCBM), soft tissue plasmacytomas (STPC) size increase, new bone lesion or STPC. International Workshop on WM (IWWM) Response Criteria was used for WM. PD: >25% immunoglobulin M (IgM) increase, progression of clinical findings or symptoms. For participants who had no PD, time to PD was censored at their last contact. | Baseline to measured progressive disease up to 40.51 months |
| Number of Participants With Adverse Events (Safety and Adverse Events) | Data are presented as number of participants who experienced serious adverse events or all other nonserious adverse events during the study including the 30-day follow-up period. A summary of serious adverse events and other nonserious adverse events is located in the Reported Adverse Event section. Safety data were collected up to 24 cycles plus 30 days of follow-up for a total up to 23.40 months. | Treatment start to 30 days after discontinuation of study treatment up to 23.40 months |
| United States |
| For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. | La Roche-sur-Yon | 85925 | France |
| For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. | Nantes | 44093 | France |
| For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. | Nîmes | 30029 | France |
| Sponsor decision |
|
| Withdrawal by Subject |
|
| Progressive Disease |
|
| Death Due to Progressive Disease |
|
| Death Due to Study Drug Related |
|
| Death Due to Adverse Events |
|
| Waldenstrom's Macroglobulinemia (WM) |
Participants diagnosed with WM received: Three 125-milligrams (mg) Enzastaurin tablets three times on Day 1 of Cycle 1 (Day 1 total dose = 1125 mg). Day 2 onwards and subsequent Cycles: Two 125-mg tablets orally twice a day (500 mg total per day). Cycle length (all cycles): 28 days. |
| BG002 | Total | Total of all reporting groups |
| years |
|
| Sex: Female, Male | Count of Participants | Participants | No |
|
| Race/Ethnicity, Customized | Count of Participants | Participants | No |
|
| Region of Enrollment | Count of Participants | Participants | No |
|
| ID | Title | Description |
|---|---|---|
| OG000 | Multiple Myeloma (MM) | Participants diagnosed with MM received: Three 125-milligrams (mg) Enzastaurin tablets three times on Day 1 of Cycle 1 (Day 1 total dose = 1125 mg). Day 2 onwards and subsequent Cycles: Two 125-mg tablets orally twice a day (500 mg total per day). Cycle length (all cycles): 28 days. |
| OG001 | Waldenstrom's Macroglobulinemia (WM) | Participants diagnosed with WM received: Three 125-milligrams (mg) Enzastaurin tablets three times on Day 1 of Cycle 1 (Day 1 total dose = 1125 mg). Day 2 onwards and subsequent Cycles: Two 125-mg tablets orally twice a day (500 mg total per day). Cycle length (all cycles): 28 days. |
|
|
| Secondary | Duration of Response (DOR) | DOR is defined as elapsed time from the first evidence of CR, PR, MR or MinR until date of progression of disease (PD). EBMT RC used for MM. CR: no serum/urine M protein for 6 wk, <5% PCBM, no LBL size/number increase, no STPC; PR: met some CR criteria plus maintain for 6 wk ≥50% SPEP and PCBM decrease, either decrease of ≥90% or <200 mg LCE, ≥50% STPC size decrease; MR: met some PR criteria plus maintain for 6 wk decrease of: 25-49% SPEP, 50-89% 24 hour urinary LCE, 25-49% PCBM, 25-49% STPC size. PD: >25% increase in SPEP, 24 hour urinary LCE, PCBM, STPC size increase, new bone lesion or STPC. IWWM RC used for WM. CR: no serum M protein, malignant cells in BM, or lymphadenopathy/organomegaly; PR: ≥50% IgM and A/O decrease; no new WM symptoms. MinR: ≥25% to <50% IgM decrease, no A/O progression; no cytopenias or clinical of WM symptoms. PD: >25% IgM increase, progression of clinical findings or symptoms. For participants who had no PD, DOR was censored at their last contact. | All participants who received at least one dose of the study drug and had complete response (CR) or partial response (PR) or minimal response (MR) or minor response (MinR). The numbers of participants censored are 1 (MM) and 13 (WM). | Posted | Median | 95% Confidence Interval | months | Time of response to time of measured progressive disease up to 38.37 months |
|
|
|
| Secondary | Time to Progressive Disease | Time to progression is defined as the elapsed time from the date of study enrollment to the date of objectively determined progressive disease (PD). European Group for Blood and Bone Marrow Transplant (EBMT) Response Criteria was used for MM. PD: >25% increase in serum monoclonal paraprotein (SPEP), 24 hour urinary light chain excretion (LCE), plasma cells in bone marrow (PCBM), soft tissue plasmacytomas (STPC) size increase, new bone lesion or STPC. International Workshop on WM (IWWM) Response Criteria was used for WM. PD: >25% immunoglobulin M (IgM) increase, progression of clinical findings or symptoms. For participants who had no PD, time to PD was censored at their last contact. | All participants who had at least one dose of the study drug. The numbers of participants censored are 7 (MM) and 33 (WM). | Posted | Median | 95% Confidence Interval | months | Baseline to measured progressive disease up to 40.51 months |
|
|
|
| Secondary | Number of Participants With Adverse Events (Safety and Adverse Events) | Data are presented as number of participants who experienced serious adverse events or all other nonserious adverse events during the study including the 30-day follow-up period. A summary of serious adverse events and other nonserious adverse events is located in the Reported Adverse Event section. Safety data were collected up to 24 cycles plus 30 days of follow-up for a total up to 23.40 months. | All participants who received at least one dose of the study drug. | Posted | Count of Participants | Participants | No | Treatment start to 30 days after discontinuation of study treatment up to 23.40 months |
|
|
|
| Other Pre-specified | Number of Participants Who Died Due to Progressive Disease During the 30 Days Following Discontinuation From Study Treatment | All participants who received at least one dose of the study drug. | Posted | Count of Participants | Participants | No | Study treatment discontinuation up to 30 days post study treatment discontinuation |
|
|
|
| 4 |
| 14 |
| 12 |
| 14 |
| EG001 | Waldenstrom's Macroglobulinemia (WM) | Participants diagnosed with WM received: Three 125-milligrams (mg) Enzastaurin tablets three times on Day 1 of Cycle 1 (Day 1 total dose = 1125 mg). Day 2 onwards and subsequent Cycles: Two 125-mg tablets orally twice a day (500 mg total per day). Cycle length (all cycles): 28 days. | 9 | 42 | 42 | 42 |
| Haemolytic anaemia | Blood and lymphatic system disorders | 15.0 | Systematic Assessment |
|
| Thrombocytopenia | Blood and lymphatic system disorders | 15.0 | Systematic Assessment |
|
| Cardiac failure | Cardiac disorders | 15.0 | Systematic Assessment | This event resulted in death. |
|
| Myocardial infarction | Cardiac disorders | 15.0 | Systematic Assessment |
|
| Diarrhoea | Gastrointestinal disorders | 15.0 | Systematic Assessment |
|
| Intestinal obstruction | Gastrointestinal disorders | 15.0 | Systematic Assessment |
|
| Nausea | Gastrointestinal disorders | 15.0 | Systematic Assessment |
|
| Peritoneal haemorrhage | Gastrointestinal disorders | 15.0 | Systematic Assessment |
|
| Volvulus | Gastrointestinal disorders | 15.0 | Systematic Assessment |
|
| Vomiting | Gastrointestinal disorders | 15.0 | Systematic Assessment |
|
| Asthenia | General disorders | 15.0 | Systematic Assessment |
|
| Chest pain | General disorders | 15.0 | Systematic Assessment |
|
| General physical health deterioration | General disorders | 15.0 | Systematic Assessment | This event resulted in death within 30 days of study discontinuation. |
|
| Abscess | Infections and infestations | 15.0 | Systematic Assessment |
|
| Clostridium difficile colitis | Infections and infestations | 15.0 | Systematic Assessment |
|
| Pneumocystis jiroveci pneumonia | Infections and infestations | 15.0 | Systematic Assessment |
|
| Sepsis | Infections and infestations | 15.0 | Systematic Assessment |
|
| Septic shock | Infections and infestations | 15.0 | Systematic Assessment | This event resulted in death. |
|
| Wound | Injury, poisoning and procedural complications | 15.0 | Systematic Assessment |
|
| Dehydration | Metabolism and nutrition disorders | 15.0 | Systematic Assessment |
|
| Back pain | Musculoskeletal and connective tissue disorders | 15.0 | Systematic Assessment |
|
| Muscular weakness | Musculoskeletal and connective tissue disorders | 15.0 | Systematic Assessment |
|
| Iiird nerve paralysis | Nervous system disorders | 15.0 | Systematic Assessment |
|
| Syncope | Nervous system disorders | 15.0 | Systematic Assessment |
|
| Renal failure acute | Renal and urinary disorders | 15.0 | Systematic Assessment |
|
| Acute respiratory distress syndrome | Respiratory, thoracic and mediastinal disorders | 15.0 | Systematic Assessment |
|
| Bronchopneumopathy | Respiratory, thoracic and mediastinal disorders | 15.0 | Systematic Assessment |
|
| Dyspnoea | Respiratory, thoracic and mediastinal disorders | 15.0 | Systematic Assessment |
|
| Thrombophlebitis | Vascular disorders | 15.0 | Systematic Assessment |
|
| Leukopenia | Blood and lymphatic system disorders | 15.0 | Systematic Assessment |
|
| Neutropenia | Blood and lymphatic system disorders | 15.0 | Systematic Assessment |
|
| Thrombocytopenia | Blood and lymphatic system disorders | 15.0 | Systematic Assessment |
|
| Vertigo | Ear and labyrinth disorders | 15.0 | Systematic Assessment |
|
| Abdominal pain | Gastrointestinal disorders | 15.0 | Systematic Assessment |
|
| Constipation | Gastrointestinal disorders | 15.0 | Systematic Assessment |
|
| Diarrhoea | Gastrointestinal disorders | 15.0 | Systematic Assessment |
|
| Nausea | Gastrointestinal disorders | 15.0 | Systematic Assessment |
|
| Vomiting | Gastrointestinal disorders | 15.0 | Systematic Assessment |
|
| Asthenia | General disorders | 15.0 | Systematic Assessment |
|
| Chest pain | General disorders | 15.0 | Systematic Assessment |
|
| Fatigue | General disorders | 15.0 | Systematic Assessment |
|
| Malaise | General disorders | 15.0 | Systematic Assessment |
|
| Oedema | General disorders | 15.0 | Systematic Assessment |
|
| Pain | General disorders | 15.0 | Systematic Assessment |
|
| Pyrexia | General disorders | 15.0 | Systematic Assessment |
|
| Bronchitis | Infections and infestations | 15.0 | Systematic Assessment |
|
| Cystitis | Infections and infestations | 15.0 | Systematic Assessment |
|
| Fungal infection | Infections and infestations | 15.0 | Systematic Assessment |
|
| Herpes zoster | Infections and infestations | 15.0 | Systematic Assessment |
|
| Nasopharyngitis | Infections and infestations | 15.0 | Systematic Assessment |
|
| Pharyngitis | Infections and infestations | 15.0 | Systematic Assessment |
|
| Sinusitis | Infections and infestations | 15.0 | Systematic Assessment |
|
| Tooth abscess | Infections and infestations | 15.0 | Systematic Assessment |
|
| Upper respiratory tract infection | Infections and infestations | 15.0 | Systematic Assessment |
|
| Urinary tract infection | Infections and infestations | 15.0 | Systematic Assessment |
|
| Head injury | Injury, poisoning and procedural complications | 15.0 | Systematic Assessment |
|
| Aspartate aminotransferase increased | Investigations | 15.0 | Systematic Assessment |
|
| Electrocardiogram qt prolonged | Investigations | 15.0 | Systematic Assessment |
|
| Weight decreased | Investigations | 15.0 | Systematic Assessment |
|
| Decreased appetite | Metabolism and nutrition disorders | 15.0 | Systematic Assessment |
|
| Hypercalcaemia | Metabolism and nutrition disorders | 15.0 | Systematic Assessment |
|
| Hyperglycaemia | Metabolism and nutrition disorders | 15.0 | Systematic Assessment |
|
| Hypoglycaemia | Metabolism and nutrition disorders | 15.0 | Systematic Assessment |
|
| Arthralgia | Musculoskeletal and connective tissue disorders | 15.0 | Systematic Assessment |
|
| Back pain | Musculoskeletal and connective tissue disorders | 15.0 | Systematic Assessment |
|
| Bone pain | Musculoskeletal and connective tissue disorders | 15.0 | Systematic Assessment |
|
| Musculoskeletal pain | Musculoskeletal and connective tissue disorders | 15.0 | Systematic Assessment |
|
| Myalgia | Musculoskeletal and connective tissue disorders | 15.0 | Systematic Assessment |
|
| Neck pain | Musculoskeletal and connective tissue disorders | 15.0 | Systematic Assessment |
|
| Osteoporosis | Musculoskeletal and connective tissue disorders | 15.0 | Systematic Assessment |
|
| Prostatic adenoma | Neoplasms benign, malignant and unspecified (incl cysts and polyps) | 15.0 | Systematic Assessment |
|
| Aphonia | Nervous system disorders | 15.0 | Systematic Assessment |
|
| Dizziness | Nervous system disorders | 15.0 | Systematic Assessment |
|
| Head discomfort | Nervous system disorders | 15.0 | Systematic Assessment |
|
| Headache | Nervous system disorders | 15.0 | Systematic Assessment |
|
| Hypoaesthesia | Nervous system disorders | 15.0 | Systematic Assessment |
|
| Neuralgia | Nervous system disorders | 15.0 | Systematic Assessment |
|
| Parkinson's disease | Nervous system disorders | 15.0 | Systematic Assessment |
|
| Peripheral sensory neuropathy | Nervous system disorders | 15.0 | Systematic Assessment |
|
| Tremor | Nervous system disorders | 15.0 | Systematic Assessment |
|
| Apathy | Psychiatric disorders | 15.0 | Systematic Assessment |
|
| Depression | Psychiatric disorders | 15.0 | Systematic Assessment |
|
| Insomnia | Psychiatric disorders | 15.0 | Systematic Assessment |
|
| Nephropathy toxic | Renal and urinary disorders | 15.0 | Systematic Assessment |
|
| Renal failure | Renal and urinary disorders | 15.0 | Systematic Assessment |
|
| Renal pain | Renal and urinary disorders | 15.0 | Systematic Assessment |
|
| Cough | Respiratory, thoracic and mediastinal disorders | 15.0 | Systematic Assessment |
|
| Dyspnoea | Respiratory, thoracic and mediastinal disorders | 15.0 | Systematic Assessment |
|
| Dyspnoea exertional | Respiratory, thoracic and mediastinal disorders | 15.0 | Systematic Assessment |
|
| Epistaxis | Respiratory, thoracic and mediastinal disorders | 15.0 | Systematic Assessment |
|
| Pneumonitis | Respiratory, thoracic and mediastinal disorders | 15.0 | Systematic Assessment |
|
| Ingrowing nail | Skin and subcutaneous tissue disorders | 15.0 | Systematic Assessment |
|
| Night sweats | Skin and subcutaneous tissue disorders | 15.0 | Systematic Assessment |
|
| Rash | Skin and subcutaneous tissue disorders | 15.0 | Systematic Assessment |
|
| Swelling face | Skin and subcutaneous tissue disorders | 15.0 | Systematic Assessment |
|
| Phlebitis | Vascular disorders | 15.0 | Systematic Assessment |
|
| Thrombosis | Vascular disorders | 15.0 | Systematic Assessment |
|
Not provided
| D014652 |
| Vascular Diseases |
| D002318 | Cardiovascular Diseases |
| D010265 | Paraproteinemias |
| D001796 | Blood Protein Disorders |
| D006402 | Hematologic Diseases |
| D006425 | Hemic and Lymphatic Diseases |
| D006474 | Hemorrhagic Disorders |
| D008232 | Lymphoproliferative Disorders |
| D008206 | Lymphatic Diseases |
| D007160 | Immunoproliferative Disorders |
| D007154 | Immune System Diseases |